Phase 2 Type 1 Diabetes Trial, Recruiting NCT03746769 Sponsor: City of Hope Medical Center Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Phase 2 Type 1 Diabetes Trial, Recruiting

NCT03746769
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 68 years old
  • You have been diagnosed with Type 1 diabetes for at least 5 years, confirmed by a specific blood test showing very low insulin production (confirm with trial site)
  • Your blood sugar levels are unstable, meaning you experience low blood sugar (below 54 mg/dl) more than once a week, and/or you cannot feel when your blood sugar drops dangerously low, and/or you had one or more severe low blood sugar episodes in the past 12 months, and/or unpredictable blood sugar levels that disrupt your daily life, and/or one or more hospital visits for diabetic ketoacidosis in the past 12 months
  • You are willing and able to follow all requirements after the procedure, including taking anti-rejection medicines, using reliable birth control, attending frequent clinic visits, keeping detailed records of blood sugar levels, insulin doses, and medications
  • You are able to give your informed consent to participate
  • You are fully vaccinated against COVID-19

Who may not be able to join:

  • Your BMI is above 33
  • Your daily insulin needs are more than 1.0 units per kilogram of body weight
  • You have significant kidney problems, shown by certain blood or urine test results (confirm with trial site)
  • You have significant liver or gallbladder disease, including abnormal liver enzyme levels, abnormal bilirubin, low albumin, liver growths, blocked liver veins, signs of liver pressure problems, or untreated gallstones
  • You have significant heart or blood vessel disease, including certain heart problems with reduced heart pumping function, a heart attack in the last 12 months, or severe circulation problems in the limbs that cannot be fixed with surgery
  • You have active, worsening damage to the blood vessels in your eyes related to diabetes
  • You have high blood pressure of 140/90 or above, even with treatment
  • You have high cholesterol or high triglyceride (fat) levels in your blood that remain too high despite treatment (confirm with trial site for specific numbers)
  • You have anemia (low red blood cell levels) or other blood disorders that need medical treatment
  • Your white blood cell count is too low (confirm with trial site)
  • You have a higher-than-normal risk of bleeding, a clotting disorder, or you take blood-thinning medicines such as heparin or warfarin
  • You currently have an unresolved infection (other than a mild skin or nail fungal infection), or a long-term infection such as tuberculosis, HIV, hepatitis B or C, CMV, or syphilis
  • A specific blood test shows you have never been exposed to the Epstein-Barr virus (EBV) (confirm with trial site)
  • You have a history of any cancer, except for certain fully removed skin cancers or cervical in-situ cancer
  • You have active peptic ulcer disease (stomach ulcers)
  • You have had gastric bypass surgery
  • You have recently not followed recommended medical treatment
  • You have an untreated psychiatric illness, or one that is likely to seriously affect your ability to follow the study requirements
  • You have previously received an organ or tissue transplant
  • You have received a live vaccine within the 60 days before joining the study
  • You have a long-term condition that requires medicines that are not allowed in this trial (confirm with trial site)
  • You have used experimental treatments or drugs within four weeks before joining the study
  • You currently misuse alcohol or substances, or smoke cigarettes (you must have stopped for more than 3 months)
  • You are pregnant, planning to become pregnant, breastfeeding, or unwilling or unable to use effective birth control throughout the study and for as long as you take anti-rejection medication
  • You do not have health insurance that will cover the cost of anti-rejection medicines and follow-up care after the study ends
  • You have any other medical condition that the study doctor believes would make it unsafe for you to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Fouad Kandeel, MD, PhD, City of Hope Medical Center

Phone: 1-866-44-ISLET(1-866-444-7538)

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
7 July 2019
Est. completion
1 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c less than or equal to 6.5% ("complete response")

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov